Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750214 | 1.00 | DPP4 (0.58) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL28257065 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL29441821 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL743047 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL572053 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL28665124 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL28257067 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL29441819 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL28181301 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL743022 | 0.84 | DPP4 (0.55) | DPP4DPP7CYP3A4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200332321-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-10-22 | — | — | US | disclosed |
| WO-2020200153-A1 | GLUCOSIDE DERIVATIVE THAT ACTS AS SGLT1 INHIBITOR AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020067930-A1 | COMPOUNDS FOR TREATING TYPE 2 DIABETES | Общество с ограниченной ответственностью "Необиотек" | 2020-04-02 | — | — | WO | disclosed |
| US-20090192326-A1 | Preparation of sitagliptin intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192326-A1 | Preparation of sitagliptin intermediate | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.